← Back to All US Stocks

electroCore, Inc. (ECOR) Stock Fundamental Analysis & AI Rating 2026

ECOR Nasdaq Electromedical & Electrotherapeutic Apparatus DE CIK: 0001560258
Updated This Month • Analysis: Mar 24, 2026 • SEC Data: 2025-12-31
Combined AI Rating
SELL
88% Confidence
AGREEMENT
STRONG SELL
92% Conf
SELL
84% Conf

📊 ECOR Key Takeaways

Revenue: $32.0M
Net Margin: -43.6%
Free Cash Flow: $-8.3M
Current Ratio: 1.38x
Debt/Equity: N/A
EPS: $-1.65
AI Rating: STRONG SELL with 92% confidence
electroCore, Inc. (ECOR) receives a SELL rating with 88% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $32.0M, net profit margin of -43.6%, electroCore, Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete ECOR stock analysis for 2026.

Is electroCore, Inc. (ECOR) a Good Investment?

Claude

electroCore is a pre-revenue profitability company with severe financial distress despite strong gross margins. Negative stockholders' equity of -$1.7M, substantial operating losses of -$13.2M, and negative free cash flow of -$8.3M indicate the company is burning cash faster than it can generate it. While 27.2% revenue growth is notable, it is insufficient to offset mounting operational inefficiencies and the company's unsustainable burn rate.

ChatGPT

electroCore is delivering solid top-line growth and exceptionally high gross margins, which suggests the underlying product economics and commercial traction are improving. However, the business remains deeply unprofitable, is burning cash, and has negative stockholders' equity, indicating that balance sheet stress and funding risk still outweigh the revenue momentum. Until operating losses narrow materially and cash generation improves, the fundamentals remain weak.

Why Buy electroCore, Inc. Stock? ECOR Key Strengths

Claude
  • + Strong gross margin of 86.8% demonstrates pricing power and product-market acceptance
  • + Revenue growth of 27.2% YoY indicates market traction in medical device segment
  • + Adequate short-term liquidity with current ratio of 1.38x and $7.0M cash reserves
ChatGPT
  • + Revenue grew 27.2% YoY, showing meaningful commercial expansion
  • + Gross margin of 86.8% indicates strong unit economics and pricing power
  • + Liquidity is still manageable near term with a 1.38x current ratio and $7.04M in cash

ECOR Stock Risks: electroCore, Inc. Investment Risks

Claude
  • ! Negative stockholders' equity of -$1.7M signals insolvency risk and threatens equity holders
  • ! Operating cash flow of -$8.2M with free cash flow margin of -25.8% indicates unsustainable business model
  • ! Total liabilities ($20.4M) exceed total assets ($18.7M) by $1.7M, creating structural balance sheet distress
  • ! Operating margin of -41.1% and net margin of -43.6% demonstrate inability to convert revenue to profitability at scale
ChatGPT
  • ! Operating margin of -41.1% and net margin of -43.6% show the business model is not yet self-sustaining
  • ! Negative stockholders' equity and liabilities above assets signal a stressed balance sheet
  • ! Negative free cash flow of -$8.25M raises the risk of future capital needs or dilution

Key Metrics to Watch

Claude
  • * Quarterly operating cash flow trend - critical for assessing path to sustainability
  • * Gross margin trajectory - must remain elevated to justify continued operations
  • * Quarterly revenue growth rate - deceleration would accelerate path to capital requirement
ChatGPT
  • * Operating cash burn and free cash flow trend
  • * Progress in operating margin and path to breakeven

electroCore, Inc. (ECOR) Financial Metrics & Key Ratios

Revenue
$32.0M
Net Income
$-14.0M
EPS (Diluted)
$-1.65
Free Cash Flow
$-8.3M
Total Assets
$18.7M
Cash Position
$7.0M

💡 AI Analyst Insight

electroCore, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

ECOR Profit Margin, ROE & Profitability Analysis

Gross Margin 86.8%
Operating Margin -41.1%
Net Margin -43.6%
ROE N/A
ROA -74.8%
FCF Margin -25.8%

ECOR vs Healthcare Sector: How electroCore, Inc. Compares

How electroCore, Inc. compares to Healthcare sector averages

Net Margin
ECOR -43.6%
vs
Sector Avg 12.0%
ECOR Sector
ROE
ECOR 0.0%
vs
Sector Avg 15.0%
ECOR Sector
Current Ratio
ECOR 1.4x
vs
Sector Avg 2.0x
ECOR Sector
Debt/Equity
ECOR 0.0x
vs
Sector Avg 0.6x
ECOR Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is electroCore, Inc. Stock Overvalued? ECOR Valuation Analysis 2026

Based on fundamental analysis, electroCore, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
-43.6%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

electroCore, Inc. Balance Sheet: ECOR Debt, Cash & Liquidity

Current Ratio
1.38x
Quick Ratio
1.24x
Debt/Equity
N/A
Debt/Assets
109.2%
Interest Coverage
-882.75x
Long-term Debt
$7.8M

ECOR Revenue & Earnings Growth: 5-Year Financial Trend

ECOR 5-year financial data: Year 2021: Revenue $5.5M, Net Income -$23.5M, EPS N/A. Year 2022: Revenue $8.6M, Net Income -$17.2M, EPS $-4.36. Year 2023: Revenue $16.0M, Net Income -$22.2M, EPS $-4.69. Year 2024: Revenue $25.2M, Net Income -$18.8M, EPS $-3.42. Year 2025: Revenue $32.0M, Net Income -$11.9M, EPS $-1.59.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: electroCore, Inc.'s revenue has grown significantly by 488% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.59 indicates the company is currently unprofitable.

ECOR Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-25.8%
Free cash flow / Revenue

ECOR Quarterly Earnings & Performance

Quarterly financial performance data for electroCore, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $6.6M -$2.5M $-0.31
Q2 2025 $6.1M -$2.7M $-0.38
Q1 2025 $5.4M -$3.5M $-0.47
Q3 2024 $4.5M -$2.5M $-0.31
Q2 2024 $3.6M -$2.7M $-0.38
Q1 2024 $2.8M -$3.5M $-0.53
Q3 2023 $2.0M -$4.0M $-0.68
Q2 2023 $2.2M -$4.9M $-1.03

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

electroCore, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$8.2M
Cash generated from operations
Capital Expenditures
$66.0K
Investment in assets
Dividends
None
No dividend program

ECOR SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for electroCore, Inc. (CIK: 0001560258)

📋 Recent SEC Filings

Date Form Document Action
Apr 14, 2026 4 xslF345X06/ownership.xml View →
Apr 14, 2026 4 xslF345X06/ownership.xml View →
Apr 1, 2026 4 xslF345X06/ownership.xml View →
Mar 20, 2026 4 xslF345X06/ownership.xml View →
Mar 19, 2026 10-K form10-k.htm View →

Frequently Asked Questions about ECOR

What is the AI rating for ECOR?

electroCore, Inc. (ECOR) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are ECOR's key strengths?

Claude: Strong gross margin of 86.8% demonstrates pricing power and product-market acceptance. Revenue growth of 27.2% YoY indicates market traction in medical device segment. ChatGPT: Revenue grew 27.2% YoY, showing meaningful commercial expansion. Gross margin of 86.8% indicates strong unit economics and pricing power.

What are the risks of investing in ECOR?

Claude: Negative stockholders' equity of -$1.7M signals insolvency risk and threatens equity holders. Operating cash flow of -$8.2M with free cash flow margin of -25.8% indicates unsustainable business model. ChatGPT: Operating margin of -41.1% and net margin of -43.6% show the business model is not yet self-sustaining. Negative stockholders' equity and liabilities above assets signal a stressed balance sheet.

What is ECOR's revenue and growth?

electroCore, Inc. reported revenue of $32.0M.

Does ECOR pay dividends?

electroCore, Inc. does not currently pay dividends.

Where can I find ECOR SEC filings?

Official SEC filings for electroCore, Inc. (CIK: 0001560258) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is ECOR's EPS?

electroCore, Inc. has a diluted EPS of $-1.65.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is ECOR a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, electroCore, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is ECOR stock overvalued or undervalued?

Valuation metrics for ECOR: ROE of N/A (sector avg: 15%), net margin of -43.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy ECOR stock in 2026?

Our dual AI analysis gives electroCore, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is ECOR's free cash flow?

electroCore, Inc.'s operating cash flow is $-8.2M, with capital expenditures of $66.0K. FCF margin is -25.8%.

How does ECOR compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -43.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.38 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 24, 2026 | Data as of: 2025-12-31 | Powered by Claude AI